MRIA9 is a chemical probe and an ATP-competitive, pan Salt-Inducible kinase (SIK) and PAK2/3 inhibitor. It exhibits IC50 values of 516 nM, 180 nM, and 127 nM for SIK1, SIK2, and SIK3, respectively. This compound is intended for research use only.
- Sensitizes SKOV3 cells to paclitaxel treatment by inducing pronounced apoptosis.
- Significantly enhances cell death in HeLa cells when combined with paclitaxel.
- Impedes centrosome function and causes mitotic spindle mispositioning in ovarian cancer cell lines.
- Prevents centrosome disjunction during the late G2 phase.
- Sensitizes ovarian cancer cells and patient-derived 3D-spheroids to paclitaxel treatment.
- Shows high oral bioavailability (F = 75-80%).